Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Rodman and Renshaw Presentation September 2012
38 slides from Cytosorbents's conference presentation, Sep 14, 2012
Slide 1: Rodman and Renshaw Presentation September 2012
Cyto Sorbents Rodman and Renshaw Presentation September 2012 OTCBB: CTSO Cyto Sorbents Corporation Working to Save Lives Through Blood Purification
Slide 2: Safe Harbor Statement
Cyto Sorbents 2 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward - looking statements and are subject to risks and uncertainties that could cause actual future events or r
Slide 3: CytoSorbents Introduction
Cyto Sorbents See Investorials Website - http://www.investorials.com/companies/ctso Investorials Video - http://www.youtube.com/watch?v= qzoH4yCW6RA Cyto Sorbents Introduction
Slide 4: Positive Analyst Recommendations
Cyto Sorbents 4 Positive Analyst Recommendations Recent Analyst Coverage Initiation
Slide 5: Management Team
Cyto Sorbents 5 Management Team • Phillip Chan, MD, PhD – Chief Executive Officer and President Board - certified internal medicine physician. MD/PhD from Yale School of Medicine. Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard. Former Partner at NJTC Venture Fund
Slide 6: Medical Advisory Board
Cyto Sorbents 6 Medical Advisory Board John Kellum, MD Professor of Critical Care Medicine & Anesthesiology University of Pittsburgh Medical Center Chair of the Sepsis Advisory Board Emil Paganini, MD Former Section Head of Dialysis and Extracorporeal Therapy Cleveland Clinic Foundation Joseph Parri
Slide 7: CytoSorbents Is Being Built On Pillars
Cyto Sorbents 7 Cyto Sorbents Is Being Built On 3 Pillars Commercialization Research And Development Partnering
Slide 8: Commercialization
Cyto Sorbents Commercialization
Slide 9: Critical Care Is a Huge Market in Need
Cyto Sorbents 9 Critical Care Is a Huge Market in Need • The sickest patients in the hospital are in the ICU • Unfortunately no effective treatments exist for common life - threatening illnesses such as sepsis, trauma, burn injury, lung injury and pancreatitis • Patients are kept alive with supporti
Slide 10: Organ Failure is the Top Cause of Death
Cyto Sorbents 10 Organ Failure is the Top Cause of Death Organ Failure occurs when vital organs stop working. It causes 50% of all deaths in the ICU Little can be done to treat or prevent it today
Slide 11: Potential to Revolutionize Critical Care
Cyto Sorbents 11 Potential to Revolutionize Critical Care Unlike supportive care therapies, Cyto Sorb ® targets the prevention or treatment of organ failure by reducing cytokine storm and decreasing inflammation
Slide 12: CytoSorb Is An Ideal Medical Device
Cyto Sorbents Cyto Sorb ® Is An Ideal Medical Device • Safe in more than 650 human treatments • Only therapy approved in the E.U. specifically for cytokine reduction and clinically proven to reduce cytokine storm in critically ill patients • Broadly indicated for use in any clinical situation where
Slide 13: Pieces to Commercialize Now in Place
Cyto Sorbents Pieces to Commercialize Now in Place • No effective therapies for life - threatening illnesses • Aging baby boomer generation driving demand • CytoSorb is an excellent product that attacks the root cause of death • Strong reception by key opinion leaders • Few competitive alternatives
Slide 14: Formal Launch Has Begun In Germany
Cyto Sorbents • Launched CytoSorb in June 2012 with hiring of direct sales team and establishment of CytoSorbents Europe GmbH subsidiary in Berlin • Focused on driving adoption and usage at many of the top 400 university and public hospitals in Germany, Austria and Switzerland • More than 40 key opi
Slide 15: CytoSorb Has Worldwide Market Potential
Cyto Sorbents Cyto Sorb Has Worldwide Market Potential 15 Middle East Europe represents a $5 - 8 billion market alone CE Mark and ISO 13485 certification will facilitate expansion outside Europe
Slide 16: U.S. Is Important But Not Essential
Cyto Sorbents U.S. Is Important But Not Essential 16 CytoSorbents could be very successful with Europe alone. However, the U.S. would double the total addressable market for CytoSorb to $10 - 15 billion and we are pursuing it
Slide 17: Focused on Clinical Data and Research
Cyto Sorbents 17 Focused on Clinical Data and Research Sepsis ARDS Burns Trauma Surgery Pancreatitis Influenza Data from multiple uses will accelerate adoption and revenue
Slide 18: Treatment was Safe
Cyto Sorbents 18 Treatment was Safe • Our European Sepsis Trial in critically ill patients demonstrated Cyto Sorb treatment was safe with no serious device related adverse events in more than 300 treatments, increasing the safe experience to more than 650 treatments overall • Treatment was well - to
Slide 19: Broad Cytokine Reduction Achieved
Cyto Sorbents Achieved statistically significant 30 - 50% reduction in key cytokines across the 7 - day treatment period. 49.1% reduction p=0.01 49.5% reduction p=0.002 36.5% reduction p=0.001 30.2% reduction p=0.002 Broad Cytokine Reduction Achieved Electronic Randomization Only: N = 43 (18 treatme
Slide 20: Faster Recovery of Lung Function in Treated Patients with High Cytokines
Cyto Sorbents Faster Recovery of Lung Function in Treated Patients with High Cytokines 20 Patients on mechanical ventilation at 28 - days (33% vs 88% control, p=0.09, N = 14; 6 treated, 8 control) (IL - 6 ≥ 1,000 pg/mL or IL - 1ra ≥ 16,000 pg/mL)
Slide 21: Increased Survival in Treated Patients with High Cytokines
Cyto Sorbents Increased Survival in Treated Patients with High Cytokines * Statistically significant 28 - day mortality benefit (0% vs 63% control, p=0.03, n=14) but small number of patients (IL - 6 ≥ 1,000 pg/mL or IL - 1ra ≥ 16,000 pg/mL) 21 *
Slide 22: Improvement in Organ Dysfunction (Age ≥ 65)
Cyto Sorbents Improvement in Organ Dysfunction (Age ≥ 65) 22 -30% -25% -20% -15% -10% -5% 0% % Reduction in MODS Score on Day 7 (versus Day 1) Control Treatment Cyto Sorb demonstrates a trend to benefit in a reduction of Multiple Organ Dysfunction Score (MODS) (28% reduction vs 9% reduction in contr
Slide 23: 14-Day Survival (Age > 65)
Cyto Sorbents 14-Day Survival (Age > 65) 50% 60% 70% 80% 90% 100% 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time to Death (Days) % Patient Survival Control Treat Statistically Significant Reduction in 14 - Day Mortality (Age ≥ 65) CytoSorb appears protective for up to 14 days in patients ≥ 65 years of age (0
Slide 24: Additional Studies
Cyto Sorbents 24 Additional Studies These intriguing early data warrant larger, prospectively designed studies • Will a “theranostics” study using high cytokine levels as an inclusion criteria yield benefit in a prospective trial? • Will more aggressive cytokine reduction in patients older than age
Slide 25: CytoSorb US Pivotal Trial Plans
Cyto Sorbents 25 Cyto Sorb US Pivotal Trial Plans • In 2007, the FDA approved our IDE application to run a small sepsis trial • Our recent European Sepsis Trial suggests certain high risk groups could benefit most from CytoSorb treatment • Our current dosing study is intended to obtain more data in
Slide 26: Research and Development
Cyto Sorbents Research and Development
Slide 27: Technology Overview
Cyto Sorbents 27 Technology Overview The heart of the technology is a biocompatible, highly porous, polymer bead that can remove a wide range of toxic substances from blood and fluids based on pore capture and surface adsorption
Slide 28: Beads Can Be Used In Many Forms
Cyto Sorbents 28 Beads Can Be Used In Many Forms Hemoperfusion “Beads in a Bag” In - line Filter
Slide 29: R&D Strategy
Cyto Sorbents • CytoSorbents invests in new product development based upon its proprietary technology that is covered by 31 issued US patents and multiple applications pending • The goals are to: 29 R&D Strategy • Develop the next generation of CytoSorb polymer • Create products that address major u
Slide 30: Leveraging Government Support
Cyto Sorbents rhabdomyolysis. A $1M Phase II application has been submitted and is pending • The US Dept of Health and Human Services awarded a $0.5M QTDP grant (2010) based on the potential of our technology to address a major unmet medical need and reduce healthcare costs • A $7M five year (2006 -
Slide 31: CytoSorbents Has a Robust Pipeline
Cyto Sorbents With strong development capabilities Cyto Sorbents Has a Robust Pipeline NAME INDICATION DESCRIPTION STATUS CytoSorb ® Severe sepsis and septic shock ARDS/ acute lung injury Burn and smoke inhalation injury Trauma Severe acute pancreatitis Complications of influenza Autoimmune disease
Slide 32: CytoSorb Use During Cardiac Surgery
Cyto Sorbents • Approximately 1 million cardiopulmonary bypass surgeries in the US and EU annually • Coronary artery bypass graft surgery • Open valve repair • Heart or lung transplantation • Cardiac defect repair • LVAD implantation • Cytokine release during the procedure is a known complication th
Slide 33: HemoDefend Protection for Blood Transfusions
Cyto Sorbents Hemo Defend Protection for Blood Transfusions • 100M+ blood transfusions worldwide annually • Hundreds of thousands to millions of people develop transfusion reactions due to contaminants in blood products • HemoDefend beads can be placed in the blood storage bag and begin removing con
Slide 34: ContrastSorb For Imaging & Interventional Radiology
Cyto Sorbents Contrast Sorb For Imaging & Interventional Radiology • IV contrast, used for interventional radiology (IR) and imaging procedures can cause kidney failure particularly in high risk patients (e.g diabetes, high blood pressure, others) • ~ 200M CT scans are performed worldwide each year
Slide 35: Business Development and Partnerships
Cyto Sorbents Business Development and Partnerships
Slide 36: Unlocking Technology Value via BD
Cyto Sorbents 36 Cyto Sorbents has an active business development program Cyto Sorb ® Hemo Defend Contrast Sorb Others Potential partners include companies involved in: • Dialysis and renal therapies • Pharmaceuticals • Critical care • Advanced materials • Blood transfusion and blood purification Go
Slide 37: CytoSorbents Is a Major Potential Growth Story
Cyto Sorbents • Cyto Sorb ® has the potential to revolutionize intensive care medicine with the goal of saving lives and reducing massive healthcare costs • Best - of - breed solution addressing a $10 - 15 billion market with little to no viable competition • Third party validation by the US Army, D
Slide 38: Phillip P. Chan, MD, PhD - CEO Deer Park Drive, Suite K Monmouth Junction,
Cyto Sorbents Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 (732) 329 - 8885 ext *823 pchan@cytosorbents.com Cyto Sorbents Corporation Working to Save Lives Through Blood Purification OTCBB: CTSO Cyto Sorbents Corporation
CytoSorbents — Rodman and Renshaw Presentation September 2012 on 6ix